The European Commission (EC) has extended the marketing authorisation for Sanofi and Regeneron's eczema drug Dupixent (dupilumab) to include adolescents, while new phase 3
AstraZeneca’s Calquence has been shown to improve progression-free survival in previously untreated mantle cell lymphoma (MCL), with an unprecedented trend towards improved overall survival